Immatics
Price & Volume
Stats
See more52W Range | $5.05-$12.41 |
Market Cap | $1.3B |
Shares Short | 5M |
Financials
See moreRevenue (12 Mos) | $37.2M |
Revenue Growth (YoY) | -59% |
Gross Profit (12 Mos) | -$163.8M |
Diluted EPS | -$1.95 |
News
See moreYahoo Finance • 29 days ago
Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting
Yahoo Finance • 2 months ago
PRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma
Yahoo Finance • 3 months ago
Immatics N.V. (IMTX) Seeing Strong Enrollment in a Key Phase 3 Trial of Drug Candidate
Yahoo Finance • 7 months ago
Immatics Announces $125 Million Underwritten Offering
About
CEO | Dr. Harpreet Singh Ph.D. |
Address | Paul-Ehrlich-Strasse 15-19, Tübingen, Germany, 72076 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 678 |